FibroGen Appoints Gerald Lema to Board of Directors
September 19 2017 - 4:35PM
FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical
company, today announced that Gerald Lema, former President of Asia
Pacific at Baxter International, has been appointed to the
Company's Board of Directors.
“We are pleased to be strengthening our board of directors with
the addition of Gerald Lema. Mr. Lema brings to FibroGen an
outstanding record as a pharmaceutical executive with extensive
commercial, financial, strategy, and Asia-specific experience,
which will be invaluable as we move towards potential approval and
commercialization of our product candidates roxadustat and
pamrevlumab,” said Thomas B. Neff, Chief Executive Officer and
Chairman of FibroGen.
Mr. Lema has more than 27 years of pharmaceutical, diagnostics,
healthcare, and consumer experience in Asia, Europe/Middle East and
Africa, U.S., and Latin America. Gerald Lema currently serves as
Partner and Representative Director of Cylon Capital, a private
investment group based in Tokyo that creates value for brands and
technologies in the Japanese and Asia Pacific markets. Prior to
Cylon Capital Mr. Lema served as President of Asia Pacific at
Baxter International from 2005 until 2015. Mr. Lema also served as
President, Japan at Baxter International since April 2007. Before
Baxter, Mr. Lema worked for 18 years at Abbott Laboratories where
he held several positions of increasing responsibility in general
management, strategy and business development. His last position
with Abbott was Corporate Vice President, Asia Pacific and
Chairman, Abbott Japan, in Tokyo. Mr. Lema currently serves as a
Director of Catalyst. Mr. Lema is co-author of Foreign Investment
through Debt-Equity Swaps, published in the MIT Sloan Management
Review. Mr. Lema is a graduate of the Stanford University Executive
Program, has a Master of Business Administration from the Freeman
School of Business at Tulane University, and has a Bachelor of
Science, Engineering from Universidad del Valle, Colombia.
About FibroGen, Inc. FibroGen, Inc.,
headquartered in San Francisco, CA with subsidiary offices in
Beijing and Shanghai, PRC, is a leading science-based
biopharmaceutical company discovering and developing a pipeline of
first-in-class therapeutics. The company applies its
pioneering expertise in fibrosis and hypoxia-inducible factor (HIF)
biology and clinical development to advance innovative medicines
for the treatment of anemia, fibrotic disease, and cancer.
Roxadustat, the company’s most advanced product candidate, is an
oral small molecule inhibitor of HIF prolyl hydroxylase activity in
Phase 3 clinical development for the treatment of anemia in chronic
kidney disease (CKD) and is entering Phase 3 development for anemia
in lower risk myelodysplastic syndromes (MDS). Pamrevlumab, a
fully-human monoclonal antibody that inhibits the activity of
connective tissue growth factor (CTGF), is in Phase 2 clinical
development for the treatment of idiopathic pulmonary fibrosis
(IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD).
FibroGen is also developing a biosynthetic cornea in China. For
more information, please visit www.fibrogen.com.
Forward-Looking Statements This release
contains forward-looking statements regarding our strategy, future
plans and prospects, including statements regarding the potential
approval and commercialization of our product candidates roxadustat
and pamrevlumab. These forward-looking statements include, but are
not limited to, statements about our plans, objectives,
representations and contentions and are not historical facts and
typically are identified by use of terms such as “may,” “should,”
“could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”
“predict,” “potential,” “continue” and similar words, although some
forward-looking statements are expressed differently. Our actual
results may differ materially from those indicated in these
forward-looking statements due to risks and uncertainties related
to the continued progress and timing of our various programs,
including the enrollment and results from ongoing and potential
future clinical trials for pamrevlumab, and other matters that are
described in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2016, and our Quarterly Report on Form 10-Q for
the quarter ended June 30, 2017, filed with the Securities and
Exchange Commission (SEC), including the risk factors set forth
therein. Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
ContactFibroGen, Inc.Karen L.
BergmanVice President, Investor Relations and Corporate
Communications1(415) 978-1433kbergman@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024